Ivabradina Doc Generici

Ivabradine, the active ingredient in Ivabradina Doc Generici, is an If channel inhibitor presented as a generic oral tablet for oral use. It lowers heart rate and is used in chronic stable angina and heart failure with reduced ejection fraction in adult patients. GNH USA supplies Ivabradina Doc Generici as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac sinus node to control heart rate, making it useful in specific cardiovascular conditions.

Chronic stable angina: reduces the frequency of angina attacks by lowering heart rate without affecting contractility. Heart failure with reduced ejection fraction: improves symptoms and reduces hospitalization by decreasing myocardial oxygen demand.

Adverse reactions may occur with ivabradine therapy.

Common Side Effects: - Visual disturbances such as luminous phenomena (phosphenes). - Bradycardia (slow heart rate). - Headache. - Dizziness. - Fatigue. - Blurred vision.

Serious or Rare Side Effects: - Severe bradycardia requiring medical attention. - Symptomatic atrial fibrillation. - Persistent visual impairment. - Hypotension leading to syncope.

Before initiating ivabradine, consider the following precautions.

Heart rate monitoring: ensure resting heart rate is ≥60 bpm before starting therapy. Severe hepatic impairment: avoid or use with caution as clearance is reduced. Sick sinus syndrome: contraindicated due to risk of excessive bradycardia. Concurrent bradycardic agents: adjust dose or monitor closely when combined with beta‑blockers or digoxin. Pregnancy and lactation: use only if potential benefit justifies potential risk. Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ivabradine may interact with several medicines; awareness of interaction severity is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) – may increase ivabradine plasma levels. - Concomitant use with other heart‑rate‑lowering agents (beta‑blockers, digoxin) – risk of severe bradycardia. - Certain antiarrhythmic drugs (e.g., amiodarone) – can potentiate bradycardic effects.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine) – may reduce ivabradine efficacy. - Calcium‑channel blockers (e.g., diltiazem, verapamil) – may modestly increase ivabradine exposure. - Antihypertensive agents – monitor blood pressure and heart rate for additive effects.